VALARTH See Sun Pharmaceutical Industries in the appOpen in app
SUNPHARMA · NSE · Pharmaceuticals

Sun Pharmaceutical Industries Ltd

What the numbers mean, from its filings and the exchange. Data as of 12 Oct 2026.
Large Cap · AMFI list Jan-Jun 2026 · Vendor sector: Basic Materials
fair low confidence No valuation within 120 days; P/E 34.9 vs peers 36.0 (8th of 18); P/B 18.9 vs peers 4.5 (18th of 18).
Statements through FY2026Prices adjusted for corporate actionsNot yet reviewed by the adversarial model

What is Sun Pharmaceutical Industries's share price today?

Sun Pharmaceutical Industries last traded at ₹1,760.00 on the NSE, as of 12 Oct 2026, 11:00 pm IST, unchanged on the day, up 5.5% over a year. Its 52-week range is ₹1,584 to ₹2,047. The live price is in the app.

₹1,760.00 0.0% today
+5.5% over 1 year · NSE, as of 12 Oct 2026, 11:00 pm IST
60 month-end closes, 31 Oct 2021 to 30 Sep 2026, adjusted for splits and bonuses
52-week range38% of the way up
Low ₹1,584High ₹2,047

What is Sun Pharmaceutical Industries's market cap?

Sun Pharmaceutical Industries's market capitalisation is about ₹4.22 lakh crore: what it would cost to buy every share at today's price. That makes it the 13th largest large cap company we cover.

₹4.2 L Cr Large Cap13th largest large cap company
Large Cap means the 100 largest listed companies, under SEBI's rules. Shares in issue are worked out from the market cap and the price. What market cap tells you →

Key facts

From the exchange
Symbol
NSE: SUNPHARMA
ISIN
INE044A01036
Cap bucket
Large Cap, 13th largest by market cap
Industry (NSE)
Healthcare › Pharmaceuticals & Biotechnology › Pharmaceuticals
Listed since
1995
Futures and options
Traded

Is Sun Pharmaceutical Industries overvalued?

Fair, with low confidence: no valuation within 120 days; P/E 34.9 vs peers 36.0 (8th of 18); P/B 18.9 vs peers 4.5 (18th of 18).

Valuation

Latest price and trailing 12 months
P/E 34.92
vs peers 36.0 · 8th of 18
Price divided by last year's earnings per share: how many years of today's profit you pay for. Learn more →
P/B 18.85
vs peers 4.5 · 18th of 18
Price divided by book value per share: what you pay for each rupee of net assets on the balance sheet. Learn more →
Market cap ₹4.22 lakh Cr
Total market value of all shares, in ₹ crore. Learn more →
Dividend yield 0.9%
vs peers 0.6% · 5th of 15
Last year's dividends as a share of today's price. Learn more →
PEG (vendor) 4.92
vs peers 2.9 · 9th of 13
P/E divided by the vendor's earnings growth figure, which it does not disclose; a P/E adjusted for how fast profits grow. Learn more →
PEG on our 3-year EPS growth 3.28
P/E divided by the 3-year EPS growth rate from the stored accounts. Learn more →
3 models could be judged
Skipped — Fair value, EPV, Graham number, Graham value, Lynch, Owner earnings: no valuation stored

Our valuation range

🔒 Pro
Value range, implied growth at today's price, and the nine models behind it: in the app.

Is Sun Pharmaceutical Industries a quality business?

Quality score 47.1, 12th of 18 in its peer set; WATCH on 30 of 30 flags judged.

Quality and risk

Data as of 12 Oct 2026
Business quality Not available
The kind of business, which sets the yardstick it is judged by. Learn more →
Quality score 47.1
vs peers 53.7 · 12th of 18
Returns, margins, leverage and consistency against its peers, out of 100. Learn more →
Risk level WATCH
30 of 30 flags judged
From flags on debt, earnings quality, dilution and price swings. Learn more →

Profitability

ROE 12.7%
vs peers 15.2% · 12th of 18
Return on equity: profit as a share of shareholders' money. Learn more →
ROCE 14.5%
vs peers 17.1% · 12th of 18
Return on capital employed: operating profit as a share of all the capital in the business, debt and equity. Learn more →
Profit margin 19.5%
vs peers 13.8% · 4th of 18
Profit after everything, as a share of revenue. Learn more →
EPS ₹48.20
Trailing 12 months
Profit for each share over the last 12 months.

Scorecard

🔒 Pro
Health scores and red flags with their values and history: in the app.
See the scorecard →
Inside the app

Get a sneak peek of Valarth

Start freeStart free
A Valarth stock page: the share price with its chart and 52-week range, valuation and profitability figures, and a scorecard of health checks.
Stock pagePrice, valuation, profitability and a scorecard of health checks for every company, each figure explained.
The Valarth stock screener: a table of companies with price, market cap, P/E, P/B, PEG, EPS and ROE, and filters down the left.
ScreenerEvery listed company, filtered on 212 figures, each with a plain-language lesson beside it.
The Valarth AI Screener answering 'Which companies will benefit from India's Project 75 submarine programme?' with a basket of four naval shipbuilders and a written thesis.
AI ScreenerAsk a question in plain English, like which companies benefit from India's Project 75. It reads the intent, builds the screen and writes the thesis.
A Valarth business-model card for State Bank of India, with a plain-language summary and statements verified against the filing.
Business modelHow a company makes money and what can hurt it, each statement checked against its annual report.
Valarth's Before the Bell edition, with the day's headline, regulator notes and sector moves.
Before the BellA morning edition before the market opens: what moved, which rule changed, and what it means for your holdings.

Has Sun Pharmaceutical Industries made money for shareholders?

Yes: +5.5% over one year and +17.3% a year over five years.

Shareholder returns

1-year return +5.5%
Price only
What the share price did over the last 12 months. Learn more →
5-year return +17.3% a year
Price only
Yearly average price return over five years, bonuses and splits adjusted. Learn more →
Wealth destroyer No
Five-year total return — price CAGR on bonus- and split-adjusted closes plus the dividend yield — below the 7% a bank fixed deposit paid. Learn more →

Returns

3Y and 5Y are yearly averages
1W
−1.1%
1M
−4.1%
3M
−8.4%
6M
+6.5%
1Y
+5.5%
3Y
+18.6%
5Y
+17.3%

Does Sun Pharmaceutical Industries pay a dividend?

Yes. Sun Pharmaceutical Industries's dividend yield is 0.91% at the latest price; the last payout was ₹5.00 a share, ex-dividend 7 Jul 2026.

Dividends

Per share, by ex-dividend date
Dividend yield0.91%
The past 12 months' dividends as a share of today's price.
7 Jul 2026 · Final₹5.00
5 Feb 2026 · Interim₹11.00
7 Jul 2025 · Final₹5.50
6 Feb 2025 · Interim₹10.50
12 Jul 2024 · Final₹5.00
Payout ratio🔒 In the app
The share of profit paid out as dividends; a very high share leaves little to reinvest.
Dividend growth, 5 years🔒 In the app
How fast the dividend per share has grown a year.
Years without a miss🔒 In the app
How many years in a row a dividend has been paid.

Is Sun Pharmaceutical Industries growing?

Revenue 3 years 11.5% a year; profit 3 years 10.7% a year; revenue 5 years 9.4% a year.

Growth

Statements through FY2026 (Mar-26)
Revenue 3 years 11.5% a year
vs peers 12.2% · 10th of 18
Compound annual growth of revenue over three years. Learn more →
Profit 3 years 10.7% a year
vs peers 19.3% · 14th of 18
Compound annual growth of net profit over three years. Learn more →
Revenue 5 years 9.4% a year
Compound annual growth of revenue over five years. Learn more →
Profit 5 years 29.9% a year
Compound annual growth of net profit over five years. Learn more →
EPS 3 years 10.7% a year
Growth in earnings per share, so dilution counts against the company. Learn more →
EPS 5 years 31.6% a year
Growth in earnings per share over five years, so dilution counts against the company. Learn more →
P/E vs own history -8.5%
vs peers 1.7% · 7th of 18
Today's P/E against its own 5-year median; negative is cheaper than its history. Learn more →

How did Sun Pharmaceutical Industries do last quarter?

Sun Pharmaceutical Industries reported revenue of ₹15,184 Cr, up 11.2% on a year earlier and a net profit of ₹2,911 Cr, up 5.3% in the Jun 2026 quarter.

Latest quarter

Jun 2026
Revenue, latest quarter₹15,184 Cr
+11.2% on a year earlier
What the company took in over the quarter.
Net profit, latest quarter₹2,911 Cr
+5.3% on a year earlier
What was left for shareholders after every cost and tax.

How does Sun Pharmaceutical Industries compare with its peers?

Compared with 17 Pharmaceuticals; 8th of 18 on P/E; 12th of 18 on quality score.

Compared with 17 Pharmaceuticals

17 companies

Sun Pharmaceutical Industries against its peers

Largest 10 of 17 peers, by market cap
CompanyMarket capP/EP/BROEROCE1YQuality 🔒Rank 🔒
Sun Pharmaceutical Industries Ltd₹4.2 L Cr34.918.912.7%14.5%+5.5%
Divis Laboratories Ltd₹2.5 L Cr84.89.416.5%21.4%+42.5%
Torrent Pharmaceuticals Ltd₹1.8 L Cr74.316.927.3%19.2%+32.4%
Zydus Lifesciences Ltd₹1.1 L Cr24.93.715.9%15.9%+12.3%
Laurus Labs Ltd₹1.1 L Cr100.510.215.1%14.9%+132.9%
Cipla Ltd₹1.1 L Cr31.22.910.6%13.9%−16.8%
Dr Reddys Laboratories Ltd₹99,911 Cr30.93.310.7%12.6%−5.2%
Mankind Pharma Ltd₹97,830 Cr47.95.013.3%13.1%−3.0%
Aurobindo Pharma Ltd₹97,411 Cr26.43.311.2%12.9%+48.9%
Lupin Ltd₹89,469 Cr15.83.523.4%27.5%−0.8%
Glenmark Pharmaceuticals Ltd₹64,714 Cr36.02.53.9%6.3%+20.1%
Peer median—36.04.515.2%17.1%+16.2%
Market cap in rupees crore; P/E and P/B on the latest price; 1Y is the price return over a year. A dash is a figure that does not apply or is not reported.

Full peer comparison

🔒 Pro
Every peer, every figure, the ranks and the quality and forensic scores side by side: in the app.

Who owns Sun Pharmaceutical Industries?

Sun Pharmaceutical Industries is held by promoters 54.5%, foreign institutions 14.5%, domestic institutions 22.2%.

Shareholding pattern

Latest filing, percent of shares
Promoters54.5%
The founders and controlling group.
Foreign institutions14.5%
Overseas funds investing through the FPI route.
Domestic institutions22.2%
Indian insurers, banks, pension and mutual funds together.
Mutual funds12.8%
Indian mutual fund schemes; part of domestic institutions.
Retail and others4.4%
Individual investors and everyone else.
Promoter shares pledged🔒 In the app
Promoter shares given as collateral for loans; a high share is a risk to watch.
Holding trend🔒 In the app
Whether promoters, foreign funds and mutual funds have been adding or selling over recent quarters.

What do analysts say about Sun Pharmaceutical Industries?

31 analysts cover Sun Pharmaceutical Industries, and the consensus is buy. A consensus is a count of opinions, not a forecast; read it beside the numbers.

Analyst consensus

31 analysts
ConsensusBuy
The rating most covering analysts give the share.
Average target price🔒 In the app
The mean of the analysts' 12-month price targets.
Upside to target🔒 In the app
How far the target sits above or below today's price.
Share rating it a buy🔒 In the app
The share of covering analysts with a buy rating.

What does Sun Pharmaceutical Industries do and what is it sensitive to?

Sun Pharmaceutical Industries Limited manufactures and sells generic medicines, branded generics, specialty pharmaceuticals, active pharmaceutical ingredients (APIs), and over-the-counter consumer healthcare products across approximately 90 countries. Sensitive to: foreign exchange (FX) volatility.

Business-model card

FY2025 · 46 verified
8Revenue
2Channels
3Regulators
4Reg. dependencies
2Sensitivities
6Costs
5Geographies

Sun Pharmaceutical Industries Limited manufactures and sells generic medicines, branded generics, specialty pharmaceuticals, active pharmaceutical ingredients (APIs), and over-the-counter consumer healthcare products across approximately 90 countries. It earns revenue by selling these products through distributors, wholesalers, and retailers to end consumers (patients), with 74.9% of turnover from exports.

Revenue by segment

year ended March 31, 2025 (Consolidated)
India33.4%
United States of America32.7%
Emerging markets19.1%
Rest of the world14.8%

Revenue engine

8 verified
India Business (33.0%)
Sells generic and branded generic medicines, OTC products, and specialty pharmaceuticals in domestic market emphasizing high-volume, lower-cost products; 33% of FY25 revenue
US Business (31.0%)
Supplies generic and specialty medicines to US market; ranked 12th largest generics company and 2nd largest by prescriptions in dermatology; 31% of FY25 revenue
Emerging Markets Business (18.0%)
Serves growth markets such as China, India, Southeast Asia and Latin America with generic and branded medicines; 18% of FY25 revenue
5 more statements
Rest of World (RoW) Business
Supplies pharmaceuticals to Western Europe, Canada, Israel, Japan, Australia, New Zealand and other markets; 14% of FY25 revenue
Active Pharmaceutical Ingredients (API) and Others
Manufactures and sells APIs across oncology, peptides, steroids, hormones and controlled substances with 400+ portfolio; 4% of FY25 revenue
Over-the-Counter (OTC) Medicines
Consumer healthcare portfolio across cough and cold, sore throat, topical analgesics, vitamins, digestives, and lifestyle products
Out-licensing arrangements
Earns revenue from product out-licensing agreements including initial up-front payments and milestone-dependent payments upon achieving clinical milestones
Profit Sharing Revenues
Sells products to business partners at base purchase price plus entitlement to profit share dependent on ultimate net sale proceeds or net profits

Customers & channels

2 verified
Distributors, wholesalers and retailers (86.0%)
Serves end consumers (patients) through distribution chain; sales to dealers/distributors represent 85.96% of total sales in FY25
B2B Customers
Engaged on ongoing basis; key areas of interest are product quality, timely supply and pricing

Regulators

3 verified
US FDA (Food and Drug Administration)
Regulates generic drug approvals in US market; faster-paced generic drug approvals by FDA create competitive intensity in US generics pricing
Indian Government Authorities
Enforce price controls and regulate domestic pharmaceutical market; government schemes such as Production Linked Incentive (PLI) scheme support industry
Global regulatory authorities (multiple jurisdictions)
Impose regulatory scrutiny and government actions to control drug prices; potential application of Most Favoured Nations model affecting pricing

Regulatory dependencies

4 verified
Price controls and value-based reimbursement in developed markets
Stricter cost control measures in developed economies influence product launches and market access planning; affect manufacturer net sales through confidential rebates and pricing pressures
Production Linked Incentive (PLI) scheme in India
Government scheme that bolsters pharmaceutical industry by encouraging investment and growth in India
Most Favoured Nations (MFN) model and tariffs
Potential application of MFN model and tariff imposition by governments could change payment models and affect pricing strategy and revenue
1 more statement
Regulatory compliance for product quality and safety
Regulatory compliance with product safety and quality standards is critical; product recalls and regulatory alerts can impair business operations and result in legal repercussions and penalties

Sensitivities

2 verified
Foreign exchange (FX) volatility
Significant volatility in forex markets, especially for emerging market currencies, affects reported growth despite growth in local currencies; Group exposed to exchange rate risk in USD, Euro, South African Rand, Japanese Yen, Brazilian Real and Russian Ruble
Interest rate movements
Floating interest rate exposure on borrowings; every 50 basis point decrease in floating rate would increase Group's profit by approximately ₹93.4 Million (FY25)

Cost inputs

6 verified
Raw materials and packing materials
Forms largest portion of cost of revenues; cost of materials consumed was ₹64,491.0 Million in FY25 with purchases of ₹67,269.4 Million during the year
Employee benefits expense
Consolidated employee benefits expense was ₹99,731.2 Million in FY25 including salaries, wages, bonus (₹88,181.1M), provident and other funds (₹6,573.9M), and staff welfare (₹4,976.2M)
Power and fuel
Manufacturing cost component; consolidated power and fuel expense was ₹4,357.2 Million in FY25
3 more statements
Selling, promotion and distribution
Largest component of other expenses; consolidated selling, promotion and distribution expense was ₹27,666.5 Million in FY25, up from ₹22,681.4 Million in FY24
Finance costs (interest expense)
Consolidated finance costs were ₹8,932.1 Million in FY25 including interest on financial liabilities at amortised cost (₹8,503.5M) and others
Professional, legal and consultancy
Consolidated professional, legal and consultancy expense was ₹15,868.6 Million in FY25, up from ₹14,126.3 Million in FY24

Geographies

5 verified
India (33.0%)
Largest pharmaceutical company in India by market share; ranked #1 across 13 different classes of doctors; Indian market projected to grow 7-10% CAGR through 2028 to reach ₹38-42 Billion; 33% of FY25 revenue
United States of America (31.0%)
12th largest generics company; 2nd largest by prescriptions in dermatology segment; faces increased competitive intensity and faster-paced generic drug approvals by FDA; 31% of FY25 revenue
Emerging Markets (China, Southeast Asia, Latin America) (18.0%)
Poised to drive next phase of global demand with projected CAGR of 10-13% through 2028; among largest Indian pharmaceutical companies in emerging markets; 18% of FY25 revenue
2 more statements
Rest of World (Western Europe, Canada, Israel, Japan, Australia, New Zealand)
Mature markets with high per capita consumption already; expected moderate future growth; 14% of FY25 revenue
Global presence across approximately 90 countries
Serves six continents: Asia, North America, Europe, Africa, South America, and Australia; exports account for 74.9% of total turnover
Each statement is checked word for word against the FY2025 annual report; the passages are in the app.

What changed recently?

Q1 FY2027 results filed (31 Jul 2026).

Change log

6 entries · newest first
  1. Results filedQ1 FY2027 results filed.
  2. Results filedQ4 FY2026 results filed.
  3. Results filedQ3 FY2026 results filed.
  4. Results filedQ2 FY2026 results filed.
  5. Results filedQ1 FY2026 results filed.
  6. Results filedQ4 FY2025 results filed.
Get alerts →Sign in to be told when any of these change.

What this page does not tell you

What could not be judged, and why. Never empty.
  • Models not runFair value, EPV, Graham number, Graham value, Lynch, Owner earnings: no valuation stored.
  • FlagsWATCH on 30 of 30 flags judged; 1 red.
  • Data gapsBusiness quality: not available yet.

What this page rests on

✓10 years of annual statements, through FY2026 (Mar-26)✓10 quarters of results✓285 months of month-end prices, adjusted for bonuses and splits○no valuation of ours yet✓business-model card FY2025 · 46 verified

Questions people ask

What is Sun Pharmaceutical Industries's share price today?

Sun Pharmaceutical Industries last traded at ₹1,760.00 on the NSE, as of 12 Oct 2026, 11:00 pm IST, unchanged on the day, up 5.5% over a year. Its 52-week range is ₹1,584 to ₹2,047. The live price is in the app.

What is Sun Pharmaceutical Industries's market cap?

Sun Pharmaceutical Industries's market capitalisation is about ₹4.22 lakh crore: what it would cost to buy every share at today's price. That makes it the 13th largest large cap company we cover.

Is Sun Pharmaceutical Industries Ltd a large cap, mid cap or small cap?

Sun Pharmaceutical Industries Ltd (SUNPHARMA) is a large cap company in AMFI's classification for Jan-Jun 2026. SEBI's buckets go by rank on six-month average market capitalisation: the top 100 are large caps, 101 to 250 mid caps, the rest small caps.

What is Sun Pharmaceutical Industries Ltd's P/E ratio?

34.92, vs peers 36.0 · 8th of 18. Price divided by last year's earnings per share: how many years of today's profit you pay for.

Is Sun Pharmaceutical Industries Ltd overvalued?

Fair, with low confidence: no valuation within 120 days; P/E 34.9 vs peers 36.0 (8th of 18); P/B 18.9 vs peers 4.5 (18th of 18).

How does Sun Pharmaceutical Industries Ltd make money?

Sun Pharmaceutical Industries Limited manufactures and sells generic medicines, branded generics, specialty pharmaceuticals, active pharmaceutical ingredients (APIs), and over-the-counter consumer healthcare products across approximately 90 countries. It earns revenue by selling these products through distributors, wholesalers, and retailers to end consumers (patients), with 74.9% of turnover from exports.

Who are Sun Pharmaceutical Industries Ltd's peers?

Compared with 17 Pharmaceuticals: Divis Laboratories Ltd, Torrent Pharmaceuticals Ltd, Zydus Lifesciences Ltd, Laurus Labs Ltd, Cipla Ltd and 12 more. The app shows how they compare on every figure.

Is this investment advice?

No. Valarth is a research and learning tool and is not a SEBI-registered investment adviser or research analyst. The figures come from the company's filings and the exchanges; what to do with them is your call.

How did Sun Pharmaceutical Industries do last quarter?

Sun Pharmaceutical Industries reported revenue of ₹15,184 Cr, up 11.2% on a year earlier and a net profit of ₹2,911 Cr, up 5.3% in the Jun 2026 quarter.

Who owns Sun Pharmaceutical Industries?

Sun Pharmaceutical Industries is held by promoters 54.5%, foreign institutions 14.5%, domestic institutions 22.2%.

Does Sun Pharmaceutical Industries pay a dividend?

Yes. Sun Pharmaceutical Industries's dividend yield is 0.91% at the latest price; the last payout was ₹5.00 a share, ex-dividend 7 Jul 2026.

What do analysts say about Sun Pharmaceutical Industries?

31 analysts cover Sun Pharmaceutical Industries, and the consensus is buy. A consensus is a count of opinions, not a forecast; read it beside the numbers.

Everything on Sun Pharmaceutical Industries, and 6,621 other companies, with 212 filters and the full peer tables

See Sun Pharmaceutical Industries in the app →See pricing